Johnson & Johnson Net Up 30% on Sales
From Bloomberg News
Johnson & Johnson’s fourth-quarter profit increased 30% as the drug maker sold more of the painkiller Duragesic and the arthritis medicine Remicade.
Net income rose to $1.4 billion, or 48 cents a share, from $1.1 billion, or 36 cents, in the year-ago period, said Johnson & Johnson. Sales climbed 14% to $9.4 billion.
Shares of New Brunswick, N.J.-based Johnson & Johnson fell 80 cents to $53.99 on the NYSE.
